JPRN-jRCT2080221196未知1 期
A phase I study of NK105 administrated weekly in patients with advanced solid malignancies.
ippon Kayaku Co., Ltd.0 个研究点目标入组 25 人开始时间: 2010年8月11日最近更新:
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed malignant solid tumour.
- •Refractory to standard therapy or for which no suitable effective standard therapy exists.
排除标准
- •Treated with taxanes within 6 months
研究者
相似试验
未知
2 期
A phase II study of NK105 for patients with previously treated advanced or recurrent gastric cancer.Gastric cancerJPRN-jRCT2080220741ippon Kayaku Co., Ltd.
未知
2 期
A dose finding study of KRN125Chemotherapy-induced neutropeniaJPRN-jRCT2080220922Kyowa Hakko Kirin Co., Ltd.
已完成
2 期
K105 Phase II Clinical trial (Breast cancer)Advanced or recurrent breast cancerJPRN-jRCT2080223812ippon Kayaku Co., Ltd.125
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ATInternational Breast Cancer Study Group (IBCSG)61
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregionalor metastatic breast carcinoma which has progressed on priortrastuzumab-based therapyMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ITInternational Breast Cancer Study Group (IBCSG)58